Insmed (NASDAQ:INSM) Price Target Raised to $101.00 at Guggenheim

Insmed (NASDAQ:INSM) had its price objective boosted by Guggenheim from $95.00 to $101.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the stock. Truist Financial reaffirmed a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a report on Friday, November 1st. Morgan Stanley upped their target price on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday. JPMorgan Chase & Co. boosted their price target on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $85.00.

Insmed Price Performance

Shares of NASDAQ INSM opened at $79.95 on Friday. Insmed has a 52-week low of $21.92 and a 52-week high of $82.04. The business has a 50-day moving average price of $72.79 and a 200 day moving average price of $73.10. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total value of $1,309,500.00. Following the sale, the chief executive officer now owns 384,960 shares of the company’s stock, valued at approximately $26,885,606.40. This represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the sale, the insider now owns 97,083 shares in the company, valued at $7,766,640. This represents a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 401,030 shares of company stock worth $30,993,629 in the last quarter. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of INSM. Steward Partners Investment Advisory LLC increased its position in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 163 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in Insmed during the 3rd quarter worth about $30,000. GAMMA Investing LLC raised its stake in Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares during the last quarter. Spire Wealth Management purchased a new position in Insmed in the 4th quarter valued at about $47,000. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.